Mitchell Steiner
CEO Veru Inc.
Seminars
Wednesday 15th July 2026
Combating Sarcopenic Obesity in Geriatrics by Combining GLP-1s with Selective Androgen Receptor Modulators (SARMs) to Prevent Muscle Loss
12:00 pm
- Adding oral selective androgen receptor modulators to standard incretin regimens to protect lean skeletal muscle mass during rapid weight loss, preventing the increased fall risk and frailty often seen in elderly patients on GLP-1s
- Utilizing advanced DEXA-based body composition analysis to prioritize “quality of weight loss” over simple BMI reduction, ensuring that weight loss translates into improved physical function and independence for the over-65 population
- Optimizing dual-therapy titration protocols to balance the appetite-suppressing effects of GLP-1s with the anabolic support of SARMs, delivering a comprehensive solution for geriatric obesity that satisfies both clinical and quality-of-life endpoints
